Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma

AKBULUT H., Icli F., Yalcin B., DEMİRKAZIK A., Onur H., Buyukcelik A., ...Daha Fazla

EXPERIMENTAL ONCOLOGY, cilt.26, sa.2, ss.149-152, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2004
  • Dergi Adı: EXPERIMENTAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.149-152
  • Anahtar Kelimeler: advanced disease, cisplatin, colorectal carcinoma, dacarbazine, irinotecan, PHASE-II, RANDOMIZED-TRIAL, FLUOROURACIL FAILURE, CANCER, LEUCOVORIN, 5-FLUOROURACIL, OXALIPLATIN, METASTASES, RESECTION, RESISTANT
  • Ankara Üniversitesi Adresli: Evet

Özet

Aim: Irinotecan is an active drug after fluorouracil (FU) failure in patients with colorectal cancer (CRC). Also a modest activity of cisplatin and dacarbazine combination in FU resistant patients have been reported. We aimed to assess the efficacy of irinotecan, cisplatin and dacarbazine combination in previously treated patients with measurable advanced CRC. Methods: Treatment schedule was irinotecan 150 mg/m(2), iv, dt; cisplatin 20 mg/m(2) and dacarbazine 200 mg/m(2) iv, d1-d3; every 21 days. 48 patients with a median age of 51 were entered the study. Results: Objective response rate was 33.3%. The overall disease stabilization rate was 75.6%. The median survival was 14 months, and the median progression-free survival was 7 months. Main toxicities were grade 2-3 vomiting (39.2%) and grade 3-4 neutropenia (17.4%). Conclusion: CPD combination seems to be very active, with acceptable safety profile, in patients with advanced CRC resistant to FUFA.